ClinicalTrials.gg

Program

AGN-193408

A development code. Also written as “AGN-193408 SR”.

In AbbVie's pipeline, PGF2 alpha receptor. Its studies are mostly in Glaucoma, Open-Angle, led by AbbVie.

Furthest: phase 2, since Jul 31, 20201 company-led study, 1 open or runningNext primary completion: Apr 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 2since Jul 31, 2020Jul 31, 2020Apr 2029phase 2 · NCT04499248
  • Named in AbbVie’s own pipeline as AGN-193408, phase 2, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 31, 2020First study: phase 2 study in Glaucoma, Open-AngleFirst studyNCT04499248 · 100 enrolled · United States, Japan

Ahead

  1. Apr 2029Primary completion: phase 2 study in Glaucoma, Open-AngleNCT04499248

TargetBeta

“PGF2 alpha receptor”the company's pipeline, read by Claude · source

Other programs on PTGFR

ProgramCompanyFurthest phaseStudies
TravoprostruleAlconphase 467

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04499248Glaucoma, Open-Angle · United States, Japan2Active, not recruitingApr 2029100

How it is read

Names in the registry

  • “AGN-193408 SR”, 2 entries

Codes read as this program: AGN193408.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.